Viatris (VTRS) News Today → Elon Musk’s Next Move Will Disrupt AI Forever (From InvestorPlace) (Ad) Free VTRS Stock Alerts $11.36 +0.20 (+1.79%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 12:03 PM | stocknews.com3 Top-Rated Pharma Stocks to Diversify Your PortfolioMay 13 at 7:24 AM | marketbeat.comViatris Q1 Earnings TranscriptMay 10 at 7:52 PM | finance.yahoo.comViatris Inc. (NASDAQ:VTRS) Q1 2024 Earnings Call TranscriptMay 9, 2024 | theglobeandmail.comStocks Rise on Fed Rate Cut HopesMay 9, 2024 | investorplace.comVTRS Stock Earnings: Viatris Meets EPS, Misses Revenue for Q1 2024May 9, 2024 | seekingalpha.comViatris Inc. 2024 Q1 - Results - Earnings Call PresentationMay 9, 2024 | reuters.comViagra maker Viatris misses revenue estimates on weak demand for older drugsMay 9, 2024 | markets.businessinsider.comViatris Inc. Q1 Profit Drops, Inline With EstimatesMay 9, 2024 | prnewswire.comViatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance RangesMay 8, 2024 | msn.comViatris Q1 Earnings Preview: Focus remains on capital allocationMay 8, 2024 | markets.businessinsider.comViatris is about to announce its earnings — here's what Wall Street expectsMay 2, 2024 | prnewswire.comViatris to Participate in the BofA Securities 2024 Health Care ConferenceMay 1, 2024 | bizjournals.comViatris partners with Unmind on mental health in the workplaceMay 1, 2024 | prnewswire.comViatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental HealthApril 24, 2024 | seekingalpha.comInflation Reduction Act: A Bullish Catalyst For Viatris Inc.April 19, 2024 | finanznachrichten.deViatris Announces Product Donations To Direct Relief of More Than 7 Million Doses of Medicine To Support Access to Medicine and HealthcareApril 16, 2024 | finance.yahoo.comViatris to Report First Quarter 2024 Financial Results on May 9, 2024April 15, 2024 | finanznachrichten.deViatris Inc.: Viatris Appoints Corinne Le Goff as Chief Commercial OfficerApril 15, 2024 | markets.businessinsider.comViatris Announces Launch Of Bioequivalent Generic For Copaxone In Canada - Quick FactsApril 8, 2024 | seekingalpha.comViatris Stock: Way Too Undervalued With $1 Billion Buyback PotentialApril 5, 2024 | reuters.comUK's Theramex sees no impact to HRT products supply after CMA probeApril 4, 2024 | msn.comViatris- Theramex deal for women's care products raises antitrust concerns in U.K.April 2, 2024 | benzinga.comViatris Stock (NASDAQ:VTRS), Quotes and News SummaryApril 2, 2024 | msn.comTeva and Viatris Granted Opportunity to Contest J&J’s Patent for Schizophrenia DrugApril 1, 2024 | msn.comTeva and Viatris revives chance to dispute J&J's schizophrenia drug patentApril 1, 2024 | reuters.comTeva, Viatris win new chance to challenge J&J schizophrenia drug patentApril 1, 2024 | stockhouse.comViatris Announces the Launch of RYZUMVl(TM) (Phentolamine Ophthalmic Solution) 0.75% in the United StatesApril 1, 2024 | finance.yahoo.comViatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United StatesApril 1, 2024 | markets.businessinsider.comViatris Announces US Commercial Launch Of RYZUMVl 0.75%March 30, 2024 | seekingalpha.comViatris Stock Is Still Worth BuyingMarch 27, 2024 | seekingalpha.comViatris Inc. (VTRS) R&D Event (Transcript)March 27, 2024 | finance.yahoo.comViatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its PipelineMarch 20, 2024 | marketbeat.comViatris Q4 Earnings TranscriptMarch 18, 2024 | globenewswire.comIdorsia and Viatris successfully close the transaction for the global research and development collaborationMarch 16, 2024 | ca.finance.yahoo.comVTRS Oct 2024 18.000 callMarch 16, 2024 | ca.finance.yahoo.comVTRS Oct 2024 10.000 putMarch 16, 2024 | finance.yahoo.comVTRS Jul 2024 18.000 callMarch 15, 2024 | reuters.comViatris generic hypertension drug does not violate J&J patents, US court saysMarch 14, 2024 | fool.comIs Viatris a Great Dividend Stock or Just a Value Trap?March 11, 2024 | fool.com2 Dirt Cheap Dividend Stocks to Buy and HoldMarch 11, 2024 | reuters.comUS FDA declines to approve Viatris's injection for multiple sclerosisMarch 5, 2024 | finance.yahoo.comViatris Inc. (NASDAQ:VTRS) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | seekingalpha.comViatris Inc. (VTRS) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | bizjournals.comViatris partners with pharmaceutical company to commercialize 2 productsFebruary 28, 2024 | msn.comVTRS Earnings: Viatris’ Top Line Declines in Q4; Boosts Buybacks by $1bFebruary 28, 2024 | investing.comIdorsia surges 14% after securing $350M from Viatris in an R&D pactFebruary 28, 2024 | sfgate.comViatris: Q4 Earnings SnapshotFebruary 28, 2024 | markets.businessinsider.comViatris Guides FY24 In Line With Estimates - UpdateFebruary 28, 2024 | msn.comViatris EPS of -$0.64, revenue of $3.83B misses by $50MFebruary 28, 2024 | msn.comViatris sets 2024 guidance above consensus; boosts share buybacks Get Viatris News Delivered to You Automatically Sign up to receive the latest news and ratings for VTRS and its competitors with MarketBeat's FREE daily newsletter. Email Address What’s Really Next for America… (Ad)Millions of Unsuspecting Americans Could be Wiped Out… Yet those who watch this bombshell exposé and prepare before it’s too late could have the chance to protect their financial future and grow their wealth significantly. Click here to stream this controversial exposé now. VTRS Media Mentions By Week VTRS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VTRS News Sentiment▼0.290.58▲Average Medical News Sentiment VTRS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VTRS Articles This Week▼164▲VTRS Articles Average Week Get Viatris News Delivered to You Automatically Sign up to receive the latest news and ratings for VTRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: BeiGene News Karuna Therapeutics News BioMarin Pharmaceutical News Dr. Reddy's Laboratories News Teva Pharmaceutical Industries News Sarepta Therapeutics News United Therapeutics News Catalent News Alnylam Pharmaceuticals News Genmab A/S News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VTRS) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsGold Set to EXPLODE!Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viatris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
